Valiant Organics (VALIANTORG)
TurnaroundFairStock Score: 17/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹324.5 |
| Market Cap | ₹909.72 Cr |
| P/E Ratio | 27.41 |
| ROCE | 2.63% |
| ROE | 4.48% |
| Dividend Yield | 0% |
| Profit Growth | 269.1% |
| Debt/Equity | 0.34 |
| Sales Growth | 6.9% |
| Promoter Holding | 37.89% |
| 52-Week Range | ₹195 — ₹394.4 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹270.99 |
Strengths
- Debt/equity is low at 0.32, providing balance sheet cushion
- Trading near book value with P/B of 1.12 and book value of ₹233.61
- Latest quarter is still profitable: ₹4 Cr net profit on ₹159 Cr sales
- Current price of ₹262.47 is well below the 52-week high of ₹397
Concerns
- Profit growth collapsed by 98.35%, with sales down 14.77%
- ROE of 3.55% and ROCE of 2.63% show very weak returns on capital
- Piotroski F-Score of 3/9 points to deteriorating financial health
- P/E of 35.42 is unreliable and expensive relative to current earnings
AI Analysis
At ₹262.47, Valiant Organics is priced at only 1.12 times book value, with book value at ₹233.61. That sounds like a Graham-style bargain, but a low price is not a bargain when earnings have collapsed. Net profit is down 98.35 per cent, sales have fallen 14.77 per cent, and the latest quarter produced just ₹4 crore profit on ₹159 crore sales. That translates into very thin margins, a return on equity of only 3.55 per cent, and a ROCE of just 2.63 per cent. As Buffett says, it is wonderful if a great company has temporary problems, but this looks like a troubled business without a proven moat. The Piotroski F-score of 3 out of 9 confirms the financial stress. The only genuine comfort is the balance sheet: debt/equity is 0.32, so the company is not drowning in debt. The dividend yield is zero, meaning retained capital is earning very little. The P/E of 35.42 is not cheap in the ordinary sense; it is a distorted ratio after profits fell off a cliff. Promoter holding at 37.89 per cent is adequate, but not high enough to signal great owner alignment. I would need to see evidence that this is a temporary cyclical downturn, not permanent impairment. I want improving quarterly sales, expanding margins, and return ratios moving back toward double digits before I call this a turnaround. Price near book gives some downside cushion, but in specialty chemicals, a weak franchise can destroy book value too. Patience is better than buying a bargain that is not yet earning.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer